# Efficacy and Safety of Empagliflozin in GSD-Ib Patients

> **NCT05960617** · PHASE2 · UNKNOWN · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Glycogen Storage Disease Type IB

## Interventions

- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT05960617
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-15
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05960617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05960617, "Efficacy and Safety of Empagliflozin in GSD-Ib Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05960617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*